Sapporo Clinical Laboratory Inc. (9776.T)
JPY 975.0
(0.83%)
JPY 975.0
(0.83%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | 1.07 Billion | 1.43 Billion | 1.57 Billion | 837.59 Million | 1.25 Billion |
| Net Income | 597.94 Million | 959.69 Million | 1.5 Billion | 1.17 Billion | 528.2 Million |
| Depreciation & Amortization | 535.59 Million | 519.09 Million | 547 Million | 271.27 Million | 244.73 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | 90.68 Million | 234.9 Million | -92.66 Million | -246.07 Million | 296.28 Million |
| Other non-cash items | -136.11 Million | 2.6 Million | 2.93 Million | -3.24 Million | 286.48 Million |
| Investing Cash Flow | -395.47 Million | -409.02 Million | -830.96 Million | -3.14 Billion | -2.91 Billion |
| Investments in PPE | -447.67 Million | -825.9 Million | -948.36 Million | -3.15 Billion | -2.98 Billion |
| Acquisitions | 29.06 Million | 477.01 Million | 314.63 Million | 2.1 Million | 90 Thousand |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | 3 Million | 3 Million | 3 Million | 3 Million | 43.98 Million |
| Other Investing Activities | 20.58 Million | -63.14 Million | 19.65 Million | -641 Thousand | 26.67 Million |
| Financing Cash Flow | -369.96 Million | -347.89 Million | -112.73 Million | 1.94 Billion | -51.63 Million |
| Debt repayment | -132.01 Million | -133.69 Million | -133.98 Million | -2 Billion | -17.39 Million |
| Dividends payments | -76.53 Million | -77.04 Million | -78.6 Million | -34.24 Million | -34.19 Million |
| Common Stock Repurchased | - | -29.21 Million | -95.02 Million | - | -45 Thousand |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | -161 Million | -1000.00 | 219.99 Million | -1000.00 | -17 Million |
| Accounts receivables | 2 Million | 76 Million | -244 Million | -165 Million | 39.41 Million |
| Accounts payables | 127.02 Million | 21.97 Million | -146.35 Million | 117.36 Million | 285.34 Million |
| Inventory | -64.24 Million | -24.03 Million | 16.66 Million | 14.99 Million | 64.53 Million |
| Other working capital | -121 Million | 160 Million | 281 Million | -212 Million | -93.01 Million |
| Cash at beginning of period | 3.65 Billion | 2.98 Billion | 2.35 Billion | 2.71 Billion | 4.42 Billion |
| Cash at end of period | 3.96 Billion | 3.65 Billion | 2.98 Billion | 2.35 Billion | 2.71 Billion |
| Capital Expenditure | -447.67 Million | -825.9 Million | -948.36 Million | -3.15 Billion | -2.98 Billion |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 312.15 Million | 673.42 Million | 629.92 Million | -367.03 Million | -1.7 Billion |
| Free Cash Flow | 629.91 Million | 604.44 Million | 625.25 Million | -2.31 Billion | -1.72 Billion |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 56 Million | 597.94 Million | 69 Million | 85 Million | 221 Million | 5 Million |
| Depreciation & Amortization | - | 535.59 Million | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 90.68 Million | - | - | - | - |
| Other non-cash items | -56 Million | -136.11 Million | -69 Million | -85 Million | -221 Million | -5 Million |
| Investing Cash Flow | - | -395.47 Million | - | - | - | - |
| Investments in PPE | - | -447.67 Million | - | - | - | - |
| Acquisitions | - | 29.06 Million | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | 3 Million | - | - | - | - |
| Other Investing Activities | - | 20.58 Million | - | - | - | - |
| Financing Cash Flow | - | -369.96 Million | - | - | - | - |
| Debt repayment | - | -132.01 Million | - | - | - | - |
| Dividends payments | - | -76.53 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | -161 Million | - | - | - | - |
| Accounts receivables | - | 2 Million | - | - | - | - |
| Accounts payables | - | 127.02 Million | - | - | - | - |
| Inventory | - | -64.24 Million | - | - | - | - |
| Other working capital | - | -121 Million | - | - | - | - |
| Cash at beginning of period | - | 3.65 Billion | - | - | - | - |
| Cash at end of period | - | 3.96 Billion | - | - | - | - |
| Capital Expenditure | - | -447.67 Million | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 312.15 Million | - | - | - | - |
| Free Cash Flow | - | 629.91 Million | - | - | - | - |
CGO
PDSSF
MACI
600757
5283
0008